AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: REXULTI (Otsuka America Pharmaceutical, Inc.) (rexulti.com)
A rare example of a low-BS website where regulatory constraints actually force high substance. The site provides specific pricing, clinical risks, and clear therapeutic boundaries without hiding behind marketing obfuscation.
To achieve a near-zero score, explicitly clarify the source of the review_count in the schema to ensure it isn’t mistaken for consumer ratings. Add direct DOI or PubMed links to the peer-reviewed clinical trial data mentioned in the prescribing info directly onto the condition pages. Ensure the IQVIA data is updated as it approaches the 12-month stale mark from the current 2026 anchor. Replace the metaphorical ‘BOOST’ language in MDD headings with clinical terminology to maintain total technical consistency.
The site exhibits exceptionally high information density, primarily due to FDA-mandated safety disclosures. Heading markers like H4 IMPORTANT SAFETY INFORMATION and H4 INDICATIONS lead to dense, technical body text detailing metabolic risks and suicidal ideation warnings. Specific nouns and metrics are abundant, such as the Wholesale Acquisition Cost (WAC) of $1,555.86 and average monthly costs like $12.51 for commercial insurance. Fluff is virtually non-existent, relegated only to minor marketing metaphors like build on your progress in the MDD section.
A validator checks tags. An AI system checks whether your identity is stable across all crawl paths. Start your free canonical interpretation to see how your URLs are actually resolved by LLMs.
There is zero semantic drift between the homepage signal and sub-page substance. The H1 Could REXULTI help? on the homepage functions as a directory that leads directly to specific, data-backed pages for MDD and AAD. The sub-pages deliver exactly what is promised: clinical definitions of the conditions, specific pricing data, and caregiver resources. The consistency is reinforced by the schema structured data which maps the MedicalWebPage to the specific MedicalCondition and Drug entities without divergence.
Stop the ROI leak caused by technical debt and strategic misalignment. Conduct an Independent Strategic Diagnosis for 1 Euro to identify high impact issues across all audit categories.
Trust theatre is nearly absent because the site relies on regulatory proof rather than social proof. While review_count is technically present in the metadata (ranging from 2 to 5), these are not displayed as marketing testimonials; instead, the site points toward external validation via FULL PRESCRIBING INFORMATION and the National Pregnancy Registry for Psychiatric Medications. The only marketing-led trust element is the caregiver story, which is transparently disclosed as a compensated ambassador role, neutralizing potential BS points.
The proof density is high, with a verified proof path to the FDA-approved label and specific financial data. The savings-cost page provides a granular breakdown of insurance types and expected copays, citing IQVIA LAAD data from December 2024 through November 2025. This ratio of verifiable evidence to vague assertion is superior to most B2B or consumer health sites.
For a high volume editorial domain example, open the Search Engine Journal Semantic HTML audit. View the SEJ Semantic HTML Audit to see how template drift and structural noise impact AI chunking.
The site follows a standard pharmaceutical ‘Patient Information’ template, which is a commodity fingerprint for the industry but serves a functional purpose. Value proposition uniqueness is high because it is tied to the specific molecule brexpiprazole rather than generic ‘wellness’ claims. While it uses industry jargon like clinical trial data and therapeutic area, these are substantiated by the inclusion of PDF links to prescribing information and IQVIA data citations from 2025.
Authority is explicitly established through Otsuka America Pharmaceutical, Inc. and supported by robust schema.org markups for the manufacturer, drug class, and administration route. There are no experts without footprints; the caregiver Natasha is presented as a compensated ambassador rather than a medical authority. Technical implementation is clean with a logical heading hierarchy and detailed JSON-LD, leaving no gaps between the claimed pharmaceutical status and the digital footprint.
The performance claims are strictly limited to FDA-approved indications, such as ‘adjunctive therapy to antidepressants.’ There are no bold, unsubstantiated claims of ‘curing’ depression; instead, the site uses measured language like ‘help build on your progress.’ Every therapeutic claim is balanced by an immediate ISI block, ensuring the marketing tone is kept in check by clinical reality.
Medical Devices, Pharma & Biotech BS: REXULTI (Otsuka America Pharmaceutical, Inc.) (rexulti.com)
The site aligns perfectly with the Pharma and Biotech category, characterized by heavy regulatory compliance, structured safety information, and clear indications for use. The content is dominated by pharmacovigilance requirements and clinical descriptors like adjunctive therapy and atypical antipsychotics.
If your entity graph is unstable, every other part of the framework inherits that instability. Study the Structured Data Framework Guide and see why schema is not markup — it is the machine readable definition of your domain.
“The score of 11 is driven by the necessary but formulaic commodity fingerprint of pharma websites and minor marketing repetition. The site excels in Information Density and Semantic Coherence, providing high-value technical and financial data that backs up every claim.”